Literature DB >> 15197468

The molecular mechanisms of congenital hypofibrinogenaemia.

G J Maghzal1, S O Brennan, V M Homer, P M George.   

Abstract

Congenital hypofibrinogenaemia is characterized by abnormally low levels of fibrinogen and is usually caused by heterozygous mutations in the fibrinogen chain genes (alpha, beta and gamma). However, it does not usually result in a clinically significant condition unless inherited in a homozygous or compound heterozygous state, where it results in a severe bleeding disorder, afibrinogenaemia. Various protein and expression studies have improved our understanding of how mutations causing hypo- and afibrinogenaemia affect secretion of the mature fibrinogen molecule from the hepatocyte. Some mutations can perturb chain assembly as in the gamma153 Cys-->Arg case, while others such as the Bbeta Leu-->Arg and the Bbeta414 Gly-->Ser mutations allow intracellular hexamer assembly but inhibit protein secretion. An interesting group of mutations, such as gamma284 Gly-->Arg and gamma375 Arg-->Trp, not only cause hypofibrinogenaemia but are also associated with liver disease. The nonexpression of these variant chains in plasma fibrinogen is due to retention in the endoplasmic reticulum, which in turn leads to hypofibrinogenaemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197468     DOI: 10.1007/s00018-004-3458-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  45 in total

1.  Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.

Authors:  Patrick W Serruys; Sigmund Silber; Scot Garg; Robert Jan van Geuns; Gert Richardt; Pawel E Buszman; Henning Kelbaek; Adrianus Johannes van Boven; Sjoerd H Hofma; Axel Linke; Volker Klauss; William Wijns; Carlos Macaya; Philippe Garot; Carlo DiMario; Ganesh Manoharan; Ran Kornowski; Thomas Ischinger; Antonio Bartorelli; Jacintha Ronden; Marco Bressers; Pierre Gobbens; Manuela Negoita; Frank van Leeuwen; Stephan Windecker
Journal:  N Engl J Med       Date:  2010-06-16       Impact factor: 91.245

2.  Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model.

Authors:  Pallav Garg; David J Cohen; Thomas Gaziano; Laura Mauri
Journal:  J Am Coll Cardiol       Date:  2008-05-13       Impact factor: 24.094

3.  Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies.

Authors:  Ajay J Kirtane; Anuj Gupta; Srinivas Iyengar; Jeffrey W Moses; Martin B Leon; Robert Applegate; Bruce Brodie; Edward Hannan; Kishore Harjai; Lisette Okkels Jensen; Seung-Jung Park; Raphael Perry; Michael Racz; Francesco Saia; Jack V Tu; Ron Waksman; Alexandra J Lansky; Roxana Mehran; Gregg W Stone
Journal:  Circulation       Date:  2009-06-15       Impact factor: 29.690

4.  Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.

Authors:  Peter Wenaweser; Joost Daemen; Marcel Zwahlen; Ron van Domburg; Peter Jüni; Sophia Vaina; Gerrit Hellige; Keiichi Tsuchida; Cyrill Morger; Eric Boersma; Neville Kukreja; Bernhard Meier; Patrick W Serruys; Stephan Windecker
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

5.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.

Authors:  Gregg W Stone; Ali Rizvi; William Newman; Kourosh Mastali; John C Wang; Ronald Caputo; Julie Doostzadeh; Sherry Cao; Charles A Simonton; Krishnankutty Sudhir; Alexandra J Lansky; Donald E Cutlip; Dean J Kereiakes
Journal:  N Engl J Med       Date:  2010-05-06       Impact factor: 91.245

6.  Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans.

Authors:  Renu Virmani; Francesco Liistro; Goran Stankovic; Carlo Di Mario; Matteo Montorfano; Andrew Farb; Frank D Kolodgie; Antonio Colombo
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

7.  Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.

Authors:  Bo Lagerqvist; Stefan K James; Ulf Stenestrand; Johan Lindbäck; Tage Nilsson; Lars Wallentin
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

8.  3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).

Authors:  Scot Garg; Patrick Serruys; Yoshinobu Onuma; Cécile Dorange; Susan Veldhof; Karine Miquel-Hébert; Krishnankutty Sudhir; Jean Boland; Kurt Huber; Eulogio Garcia; Jan A M te Riele
Journal:  JACC Cardiovasc Interv       Date:  2009-12       Impact factor: 11.195

9.  Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.

Authors:  Edoardo Camenzind; William Wijns; Laura Mauri; Eric Boersma; Keyur Parikh; Volkhard Kurowski; Runlin Gao; Christoph Bode; John P Greenwood; Anthony Gershlick; William O'Neill; Patrick W Serruys; Brenda Jorissen; P Gabriel Steg
Journal:  Am Heart J       Date:  2009-12       Impact factor: 4.749

10.  First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial.

Authors:  Ian T Meredith; John Ormiston; Robert Whitbourn; I Patrick Kay; David Muller; Raoul Bonan; Jeffrey J Popma; Donald E Cutlip; Peter Fitzgerald; Ross Prpic; Richard E Kuntz
Journal:  EuroIntervention       Date:  2005-08       Impact factor: 6.534

View more
  5 in total

1.  Hypodysfibrinogenaemia due to production of mutant fibrinogen alpha-chains lacking fibrinopeptide A and polymerisation knob 'A'.

Authors:  Silja Vorjohann; Richard J Fish; Christine Biron-Andréani; Chandrasekaran Nagaswami; John W Weisel; Pierre Boulot; Lionel Reyftmann; Philippe de Moerloose; Marguerite Neerman-Arbez
Journal:  Thromb Haemost       Date:  2010-08-30       Impact factor: 5.249

2.  Why dysfibrinogenaemias still matter.

Authors:  John W Weisel
Journal:  Thromb Haemost       Date:  2009-09       Impact factor: 5.249

3.  A novel fibrinogen mutation: FGA g. 3057 C > T (p. Arg104 > Cys) impairs fibrinogen secretion.

Authors:  R Marchi; M Linares; H Rojas; A Ruiz-Sáez; M Meyer; A Casini; S O Brennan
Journal:  BMC Hematol       Date:  2017-12-22

4.  Prenatal and Peripartum Management of Patients with Hypofibrinogenemia Resulted in Two Successful Deliveries.

Authors:  Yuko Teraoka; Hiroshi Miyoshi; Kumi Oshima; Satoshi Urabe; Norifumi Tanaka; Yoshiki Kudo
Journal:  Case Rep Obstet Gynecol       Date:  2017-02-14

Review 5.  Hepatic and Extrahepatic Sources and Manifestations in Endoplasmic Reticulum Storage Diseases.

Authors:  Francesco Callea; Paola Francalanci; Isabella Giovannoni
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.